Table 2

Ongoing clinical trials with PARP inhibitors (PARPi), anti-VEGF, ixabepilone and capecitabine drugs, divided by metastatic, neoadjuvant or adjuvant setting, regimen and efficacy

Trial ID/numberPhaseSettingRegimenEfficacyReference
OlympiAD
NCT00494234
IIIMetastatic (HER2-negative with gBRCAm)Olaparib (PARPi) versus chemotherapyProgression-free survival improved 75
ABRAZO
NCT02034916
IIMetastatic (with gBRCAm)Talazoparib (PARPi) in patients previously exposed to platinum or multiple cytotoxic regimensTalazoparib is well tolerated and has promising antitumour activity 143
EMBRACA
NCT01945775
IIIMetastaticTalazoparib (PARPi) in patients who have received prior chemotherapy for metastasisOngoing, no results published 144
PARTNER
NCT03150576
II/IIINeoadjuvant (TNBC or gBRCAm)Adding olaparib (PARPi) to neoadjuvant platinum or multiple prior cytotoxic regimensOngoing, no results published 145
NCT02282345IINeoadjuvant (invasive BC and deleterious BRCAm)Talazoparib (PARPi)Ongoing, no results published 146
NCT00148694IINeoadjuvant (TNBC)CisplatinpCR=22% 147
NCT02199418IINeoadjuvantPaclitaxel and cisplatinpCR=64.7% (in TNBC) 100
NCT00483223IIMetastatic (TNBC)Cisplatin or carboplatinORR=25.6% 148
NANAMetastaticCarboplatin and paclitaxelORR=56.6% (in TNBC) 149
BEATRICE
NCT00528567
IIIAdjuvant (TNBC)Bevacizumab (anti-VEGF)No differences in overall survival; prior patient selection must be performed. 71
NCT01069796IIMetastatic (TNBC)Bevacizumab, paclitaxel, capecitabineOngoing, no results published 72
TITAN
NCT00789581
IIIAdjuvant (TNBC)Ixempra (ixabepilone) versus TaxolNo differences in disease-free survival and overall survival with Ixempra 73
NCT00633464IIMetastatic (TNBC)Ixabepilone and ixabepilone + cetuximab (EGFR inhibitor)Time to response improved in combination, progression-free survival similar 74
  • BC, breast cancer; gBRCAm, germline BRCA mutation; NA, non applicable; ORR,¬†objective response rate; PARPi, poly (ADP-ribose) polymerase inhibitor; pCR, pathological complete response; TNBC, triple negative breast cancer; EGFR, epidermal growth factor receptor.